Cargando…

Inclusion in limited distribution drug network reduces time to dalfampridine access in patients with multiple sclerosis at a health-system specialty pharmacy

BACKGROUND: Dalfampridine improves walking speed in patients with multiple sclerosis (MS), but accessing specialty medications such as dalfampridine can be hindered by insurance restrictions, high costs, and limited distribution networks (LDNs) imposed by manufacturers. Some integrated health-system...

Descripción completa

Detalles Bibliográficos
Autores principales:	Peter, Megan E, Markley, Brandon, DeClercq, Josh, Choi, Leena, Givens, Gabrielle, Zuckerman, Autumn D, Banks, Aimee
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Academy of Managed Care Pharmacy 2021
Materias:	Research Brief
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391274/ https://www.ncbi.nlm.nih.gov/pubmed/33506731 http://dx.doi.org/10.18553/jmcp.2021.27.2.256

Ejemplares similares

Primary medication nonadherence rates to specialty disease-modifying antirheumatic drugs for rheumatoid arthritis within a health system specialty pharmacy
por: Petry, Laura, et al.
Publicado: (2023)

Adherence and persistence in patients with rheumatoid arthritis at an integrated health system specialty pharmacy
por: Peter, Megan E, et al.
Publicado: (2021)

Specialty pharmacist integration into an outpatient neurology clinic improves pimavanserin access
por: Livezey, Sabrina, et al.
Publicado: (2021)

Impact of specialty pharmacist integration on time to medication access for pimavanserin
por: Livezey, Sabrina, et al.
Publicado: (2019)

Predicting time to medication access for hematologic malignancies: the impact of an integrated specialty pharmacy and limited distribution drug networks
por: Zuckerman, Autumn D., et al.
Publicado: (2019)

An Integrated Health-System Specialty Pharmacy Model for Coordinating Transitions of Care: Specialty Medication Challenges and Specialty Pharmacist Opportunities
por: Zuckerman, Autumn D., et al.
Publicado: (2019)

Development of a collaborative pharmacy practice agreement to improve efficiency and management of prescribing in a renal transplant clinic
por: Chelewski, Rachel, et al.
Publicado: (2019)

High rates of medication adherence in patients with pulmonary arterial hypertension: An integrated specialty pharmacy approach
por: Shah, Nisha B., et al.
Publicado: (2019)

Low rates of primary medication nonadherence in patients prescribed oral oncology agents across health system specialty pharmacies
por: Zuckerman, Autumn, et al.
Publicado: (2023)

988. Overcoming Prescriber Concerns through Successful Access and Affordability of PrEP
por: Whelchel, Kristen, et al.
Publicado: (2020)

Pharmacist Interventions to Improve Specialty Medication Adherence: Study Protocol for a Randomized Controlled Trial
por: Kibbons, Amanda M., et al.
Publicado: (2020)

981. Extended Adherence and Persistence to HIV PrEP in a Multidisciplinary PrEP Clinic
por: Whelchel, Kristen, et al.
Publicado: (2020)

Prescriber utilization of dalfampridine extended release tablets in multiple sclerosis: a retrospective pharmacy and medical claims analysis
por: Jara, Michele, et al.
Publicado: (2014)

Impact of extended-release dalfampridine on walking ability in patients with multiple sclerosis
por: Hayes, Keith C
Publicado: (2011)

Dalfampridine: Review of its Efficacy in Improving Gait in Patients with Multiple Sclerosis
por: Sahraian, M.A., et al.
Publicado: (2011)

A Massive Overdose of Dalfampridine
por: Fil, Laura J., et al.
Publicado: (2015)

Clarification of Dalfampridine Labeled Indications
por: Rabinowicz, Adrian L., et al.
Publicado: (2012)

Incidence and Impact of Persistent Viremia on SVR Rates in Patients Receiving Direct-Acting Antiviral Therapy
por: Carver, Alicia B, et al.
Publicado: (2020)

Dalfampridine sustained-release for symptomatic improvement of walking speed in patients with multiple sclerosis
por: Jeffery, Douglas R, et al.
Publicado: (2010)

Oral Dalfampridine Improves Standing Balance Detected at Static Posturography in Multiple Sclerosis
por: Prosperini, Luca, et al.
Publicado: (2014)

Study on Dalfampridine in the treatment of Multiple Sclerosis Mobility Disability: A meta-analysis
por: Shi, Jianzhen, et al.
Publicado: (2019)

Dalfampridine in the treatment of multiple sclerosis: a meta-analysis of randomised controlled trials
por: Zhang, Enyao, et al.
Publicado: (2021)

Dalfampridine effects on cognition, fatigue, and dexterity
por: Korsen, Melanie, et al.
Publicado: (2016)

Pharmacologic management of HCV treatment in patients with HCV monoinfection vs. HIV/HCV coinfection: Does coinfection really matter?
por: Zuckerman, Autumn D., et al.
Publicado: (2019)

Impact of specialty pharmacy taking ownership of the prior authorization process of multiple sclerosis specialty medications to increase access to infusible disease-modifying therapy (DMT)
por: Whetstone, Miranda, et al.
Publicado: (2019)

The Emergence of Specialty Pharmacy
por: Vanscoy, Gordon J.
Publicado: (2020)

The Reemergence of Specialty Pharmacy
por: Vanscoy, Gannon, et al.
Publicado: (2020)

Integrating high touch specialty pharmacy services within a neurology clinic to improve medication access and affordability
por: Newman, Brandon, et al.
Publicado: (2019)

Identification of metabolites of dalfampridine (4-aminopyridine) in dog and rat
por: Caggiano, Anthony, et al.
Publicado: (2013)

Objective and subjective measures of dalfampridine efficacy in clinical practice
por: Klineova, Sylvia, et al.
Publicado: (2018)

Dalfampridine Prior Authorization Program: A Cohort Study
por: Gleason, Patrick P., et al.
Publicado: (2013)

Patient Perspectives and Experience with Dalfampridine Treatment in Multiple Sclerosis-Related Walking Impairment: The Step Together Program
por: Crayton, Heidi, et al.
Publicado: (2014)

Safety profile of dalfampridine extended release in multiple sclerosis: 5-year postmarketing experience in the United States
por: Jara, Michele, et al.
Publicado: (2015)

Post-marketing safety surveillance of dalfampridine for multiple sclerosis using FDA adverse event reporting system
por: Xiong, Rui, et al.
Publicado: (2023)

Exploring healthcare providers’ experiences with specialty medication and limited distribution networks
por: Peter, Megan E., et al.
Publicado: (2022)

Management of specialty drugs, specialty pharmacies and biosimilars in the United States
por: Brook, Richard A., et al.
Publicado: (2019)

The effectiveness of amantadine and dalfampridine in improving fatigue in patients with multiple sclerosis: A randomized, double-blind, clinical trial
por: Sadeqi, Yasaman, et al.
Publicado: (2022)

Best Practices in Specialty Pharmacy Management
por: Patterson, Courtney J.
Publicado: (2013)

Adherence to oral oncolytics filled through an internal health-system specialty pharmacy compared with external specialty pharmacies
por: Academia, Emmeline C, et al.
Publicado: (2021)

Estimation of the effect of dalfampridine-ER on health utility by mapping the MSWS-12 to the EQ-5D in multiple sclerosis patients
por: Limone, Brendan L, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_qtaq88san13jgi2f56pv5aeaab